Level of CD 20-expression and efficacy of Rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia
Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2002]
|
| In: |
Leukemia and lymphoma
Year: 2002, Volume: 43, Issue: 1, Pages: 149-151 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428190210178 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/10428190210178
|
| Author Notes: | Jolanta Perz, Julian Topaly, Stefan Fruehauf, Manfred Hensel Anthony D. Ho (Department of Internal Medicine V, University of Heidelberg) |
| Summary: | Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment. |
|---|---|
| Item Description: | Elektronische Reproduktion der Druckausgabe Gesehen am 14.12.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428190210178 |